AI Reality Check In Drug Development: What's Real And What's Missing

Artificial intelligence is rapidly reshaping drug discovery, with billions of dollars flowing into technologies designed to identify stronger candidate molecules and improve the probability of success before a drug ever reaches the clinic. AI is also gaining ground in drug development, including in the analysis and modeling of clinical data, while new FDA initiatives are testing how it could support earlier, real-time signal detection. But as interest in AI continues to grow, the industry is increasingly asking a more practical question: What is creating meaningful value today, and what is still missing?

Veteran drug developer and TruTechnologies co-founder Dr. Richard Graham will be joined by oncology drug development leader Dr. Mark Lackner and life sciences patent attorney Matthew Bresnahan to examine that question from across the drug development landscape. Together, they will bring perspectives spanning scientific discovery, clinical trial execution, and the evolving patent considerations surrounding AI-enabled innovation.